{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"27","value":"21"},{"groupId":"OG001","lowerLimit":"14","upperLimit":"30","value":"18"},{"comment":"The upper level of 95% Confidence interval is not reached.","groupId":"OG002","lowerLimit":"9.2","upperLimit":"NA","value":"21"},{"comment":"Median and 95% confidence intervals are not reached due to the small number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"OS based on the Kaplan-Meier method is defined as the duration from randomisation to the date of death due to any cause, or is censored at date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation\n\nStandard Chemotherapy: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.\n\nIpilimumab and Nivolumab: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population is comprised of intention-to-treat patients. One patient in the experimental arm of the Chemo Cohort was excluded due to a randomization error, with no treatment or follow-up data available.","reportingStatus":"POSTED","timeFrame":"Minimum follow-up is 24 months after randomisation. Median follow-up for survival is of 33 months with range (3 months - 47 months).","title":"Median Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}